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Abstract
Background
Pre-transplant infusion of rabbit anti-T cell globulin (ATG) is increasingly used as prevention
of graft-versus-host disease (GVHD) after allogeneic peripheral blood stem cell transplanta-
tion (PBSCT). However, the precise impact of pre-transplant ATG on immune recovery after
PBSCT is still poorly documented.
Methods
In the current study, we compared immune recovery after myeloablative PBSCT in 65
patients who either received (n = 37) or did not (n = 28) pre-transplant ATG-Fresenius
(ATG-F). Detailed phenotypes of circulating T, B, natural killer (NK) and invariant NKT
(iNKT) cells were analyzed by multicolor flow cytometry at serial time-points from day 40 to
day 365 after transplantation. Thymic function was also assessed by sjTREC quantification.
Serious infectious events were collected up to 2 years post-transplantation.
Results
Pre-transplant ATG-F had a prolonged (for at least up to 1-year) and selective negative
impact on the T-cell pool, while it did not impair the recovery of B, NK nor iNKT cells. Among
T cells, ATG-F selectively compromised the recovery of naïve CD4+, central memory CD4+
and naïve CD8+ cells, while it spared effector memory T and regulatory T cells. Levels of
sjTRECs were similar in both cohorts at 1-year after PBSCT, suggesting that ATG-F unlikely
impaired thymopoiesis at long-term after PBSCT. Finally, the incidence and rate of serious
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infections were similar in both groups, while ATG-F patients had a lower incidence of grade
II-IV acute graft-versus-host disease.
Conclusions
Pre-transplant ATG-F induces long-lasting modulation of the circulating T-cell pool after
myeloablative PBSCT, that may participate in preventing graft-versus-host disease without
deeply compromising anti-pathogen defenses.
Introduction
The use of peripheral blood stem cells (PBSC) instead of bone marrow as graft source for allo-
geneic stem cell transplantation has resulted in increased incidences of both grade III-IV acute
and extensive chronic graft-versus-host disease (GVHD) [1]. This prompted several groups of
investigators to assess the ability of pre-transplant infusion of rabbit anti-T cell globulins
(ATG) to prevent GVHD after PBSC transplantation (PBSCT) [2–7]. Rabbit ATG are poly-
clonal antibody preparations corresponding to the purified IgG fraction of sera from rabbits
that were immunized with human T cells. Due to their relatively long half-life in human plasma
(up to 6 weeks), ATG preparations can persist in blood for several weeks after infusion [8, 9]
and destroy donor T cells passively transferred with the graft.
Effects of pre-transplant ATG on GVHD prevention after stem cell transplantation have
been demonstrated in a number of recent studies [2–7]. Most of the studies performed in
patients given myeloablative conditioning have shown that ATG decreased the incidence of
both acute and chronic GVHD, without increasing relapse risk [3, 5, 6]. Similarly, ATG has
been reported to successfully prevent GVHD after reduced intensity conditioning (RIC) trans-
plantation, while its impact on relapse incidence in that setting remained controversial. Hence,
in a large CIBMTR study including patients who underwent RIC transplantation for various
hematological malignancies, Soiffer et al. reported that ATG was associated with a higher risk
of relapse [7]. To the contrary, in a large EBMT study of patients given RIC PBSCT for acute
myeloid leukemia, the authors observed that ATG did not result in a higher relapse risk, unless
if it was given at high doses [2]. Eventually, in both the RIC and myeloablative settings, con-
cerns have also risen about a higher incidence of infectious complications with ATG, specifi-
cally when used at high doses [10–12].
The most widely used rabbit ATG preparations in Europe are ATG-T (Thymoglobulin,
Genzyme/Sanofi) that is produced by rabbit immunization against human thymocytes, and
ATG-F (Fresenius/Neovii) that is produced by rabbit immunization against the human T lym-
phoblastoid cell line Jurkat [13]. Both ATG preparations contain a diverse spectrum of anti-
body specificities directed against T-cell epitopes that can mediate T-cell depletion in blood
and in lymphoid tissues through induction of activation-associated apoptosis and comple-
ment- or natural killer (NK)-cell-dependent lysis. However, because of their polyclonal nature,
ATG preparations do not exclusively target T cells, but also other immune cells. Hence,
ATG-T contains antibodies against multiple antigens that are expressed on various subsets of
T, B, NK, granulocyte, monocyte/macrophage and dendritic cells, as well as on thymic stromal
cells [13, 14]. The precise spectrum of ATG-F has not been studied extensively yet. However,
since ATG-F is produced by immunization against homogeneous Jurkat cells, it is likely that its
spectrum is smaller (e.g. anti-CD4 and anti-HLA-DR antibodies are lacking in ATG-F [13]).
This may be relevant given recent evidences of an immunoregulatory activity of several anti-
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CD4 antibodies [15]. Further, in contrast to ATG-T [14], ATG-F does not include antibodies
directed against thymic stromal cells. Therefore, the impact of ATG on thymic function may
likely differ according to ATG formulation.
Despite being increasingly used, the impact of ATG on immune recovery after PBSCT has
not been widely studied. Further, most published studies investigated ATG-T [16–18]. In the
largest published study, Bosch et al. observed that ATG-T delayed the recovery of naive and
memory CD4+T cells as well as of naive CD8+T cells after myeloablative PBSCT.[16] Other
groups of investigators have observed a negative impact of ATG-T on naive T-cell output by
the thymus after PBSCT [17, 19]. Only few studies have specifically analyzed the effects of
ATG-F on immune recovery after stem cell transplantation [20, 21]. In a pediatric population,
Mensen et al. retrospectively showed that ATG-F patients had a similar long-lasting T-cell defi-
ciency as patients given ATG-T at standard doses [20]. However, they did not analyze T-cell
subpopulations in details. Recently, Roll et al. focused on the effects of ATG-F on B cell recov-
ery after allogeneic transplantation, and suggested that ATG-F also negatively impacted early
memory B-cell reconstitution [21]. Here, we report one of the largest studies assessing the
impact of ATG-F on the recovery of a large variety of lymphoid cell subsets as well as on thy-
mic function after myeloablative PBSCT.
Patients and Methods
Patients
We performed a retrospective study of patients who underwent a first allogeneic PBSCT with-
out ex-vivo T-cell depletion after myeloablative conditioning at our institution between January
2000 and September 2012. Myeloablative conditioning regimens were defined as those based
on high dose total body irradiation (TBI) ( 500 cGy single dose or 800 cGy fractionated
dose), high doses of Busulfan (> 8 mg/kg orally) or high doses of other alkylating agents [22].
Grafts were obtained from HLA-identical sibling donors or 9-10/10 HLA-A,-B,-C,-DR,-DQ
unrelated donors. According to institutional guidelines, pre-transplant ATG-F was not given
before year 2003. Between 2003 and 2006, it was only used in patients transplanted for non-
malignant diseases. Since 2006 and thereafter, use of pre-transplant ATG-F was given to all
patients with the exception of those with very high-risk malignant diseases. ATG-F was gener-
ally given for 3 consecutive i.v. injections (15mg/kg on days 3, 2 and 1 before transplantation).
All patients provided written informed consent for use of protected health data for research
and for blood sample collection, in accordance with the Declaration of Helsinki. Written
informed consent from caretakers was obtained on behalf of the minor patients. This study
was approved by our institutional review board (Comité d’Ethique Hospitalo-Facultaire Uni-
versitaire de Liège, study number: B70720096240).
Immune analyses were also performed on blood samples from 22 healthy age-matched vol-
unteers, after having obtained their written informed consent.
Clinical monitoring after PBSCT
T-cell chimerism was assessed at days 40, 100, 180, 365 after PBSCT and yearly thereafter. Chi-
merism analyses were carried out after T-cell isolation with the RosetteSep technology (Stem-
Cell Technologies, Vancouver, Canada) and were performed using either fluorescence in situ
hybridization of sex chromosomes in cases of sex-mismatched donor/recipient pairs or PCR-
based analysis of polymorphic microsatellite regions (multiplex PCR) in cases of sex-matched
donor/recipient pairs. Graft rejection was defined as occurrence of< 5% donor T-cell chime-
rism. Disease evaluation was also routinely carried out on days 40, 100, 180, 365 after PBSCT
and yearly thereafter.
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Postgrafting immunosuppression mostly consisted of a calcineurin inhibitor (cyclosporine
or tacrolimus) combined with methotrexate. Acute GVHD was graded using the 1994 consen-
sus conference standard criteria [23]. Chronic GVHD was diagnosed based on diagnostic or
distinctive features and was graded in mild, moderate or severe form, as proposed by the 2005
National Institutes of Health (NIH) Consensus criteria [24]. Grade 2–4 acute GVHD as well as
moderate/severe chronic GVHD were usually treated with prednisolone as first line therapy,
supplemented by other immunosuppressive drugs for some patients.
All patients were treated in laminar airflow or high-efficiency particulate absorption air fil-
tered rooms during the early post-transplant period, until they had an absolute neutrophil
count above 1 x 109/L. Infection prophylaxis usually consisted of levofloxacine, fluconazole,
acyclovir and co-trimoxazole or aerosolized pentamidine (S1 Methods). Patients were screened
weekly for CMV by antigenemia and/or PCR in blood. Pre-emptive therapy with ganciclovir
was initiated after a positive antigenemia or PCR and discontinued after at least two consecu-
tive negative results. Epstein-Barr virus (EBV) viral load was not assessed before 2006. Since
2006, it was quantified by PCR upon clinical suspicion and therapy with rituximab was initi-
ated if it was> 10,000 copies/mL. A pet-CT was usually performed in these cases, in order to
exclude EBV-mediated post-transplant lymphoproliferative disorder (PTLD).
Serious infections after PBSCT
Only serious infections, potentially associated with clinical compromise, were considered in
this analysis. They were defined, as previously described [25]:
• Serious bacterial infections-These included bacterial infections of any organ site requiring i.
v. therapy and/or hospitalization. Bacterial infections were either microbiologically proven
or presumed based on the combination of clinical presentation and response to treatment
with antibiotics. Bacteremia by coagulase-negative staphylococci, Micrococcus spp and sap-
rophytic Corynebacterium spp were excluded in this analysis, as well as infections of intra-
vascular devices because of possible exogenous contamination and potential for reporting
bias.
• Serious viral infections–These included CMV and EBV viremia requiring treatment, and
other documented invasive viral infections requiring i.v. therapy and/or hospitalization
(such as disseminated form or visceral involvement of herpes family virus infections, adeno-
virus disease, B or C viral hepatitis and lower respiratory tract infections by respiratory
viruses). CMV disease was diagnosed according to previously reported criteria [26].
• Serious fungal infections–These included any invasive fungal infections. Invasive aspergillo-
sis was defined as proven, probable or possible according to standard criteria [27]. Interstitial
pneumonia caused by Pneumocystis Jiroveci was considered as fungal infection.
• Serious parasitic infections–These included toxoplasmosis and other invasive parasitic
infections. Infection-related mortality was defined as death from infection as the primary
cause of death, basing on the Copelan hierarchical scheme for causes of death assignment
[28].
Immune recovery monitoring
Phenotypes of circulating lymphocytes by flow cytometry. Basic phenotypes of circulat-
ing lymphocytes was prospectively assessed by flow cytometry on fresh heparinized peripheral
blood samples collected on days 40, 60, 80, 100, 120, 180 and 365 after PBSCT. Cells were
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characterized using 4-color flow cytometry after red blood cell lysis, as previously described
[29, 30].
More detailed lymphoid cell phenotypes were retrospectively assessed on cryopreserved
peripheral blood mononuclear cells (PBMCs) that were prospectively collected on days 40,
100, 180 and 365 after PBSCT, as previously described [31]. Briefly, PBMCs were isolated by
density gradient centrifugation (Ficoll-Paque; GE Healthcare) from fresh heparinized blood
samples and then frozen. Lymphocyte subsets were analyzed using 8-color flow cytometry. The
following antibodies were used: anti-CD4 PercP (SK3), anti-CD45RA APC (HI 100), anti-
CD31 PE (L133.1), anti-CD19 APCCy7 (SJ25C1), anti-IgD biot (IA6-2), anti-CD27 PE
(M-T271), Anti-CD3 V500 (SP34-2), anti-CD56 V450 (B159) and anti-CD16 FITC (3G8)
from BD Biosciences (San Diego, CA, USA); anti-CD8 FITC (HiT8a), anti-CCR7 PeCy7
(3D12), anti-CD25 PE (BC96), anti-CD127 biot (eBioRDR5), anti-TCRVα24Jα18 PE (6B11),
streptavidine eF450, streptavidine APCCy7 and streptavidine PeCy7 from e-Bioscience (San
Jose, CA, USA); anti-FoxP3 FITC 206D from Biolegend (San Diego, CA, USA); anti-TCR
Vβ11 biot (C21) from Analis (Namur, Belgium). Intracellular staining was performed using
human intracellular FoxP3 staining kit (Biolegend, San Diego, CA, USA) according to the
manufacturer’s instructions. Lymphoid cells were gated on forward versus side-scatter plots.
Cells were acquired on a FACSCanto II (Becton Dickinson) and data were analyzed with
FlowJo software (7.0, Tree Star Inc., San Carlos, CA). A minimum of 100 events in the parent
population was considered mandatory to ensure reliable subset analyses and data were not con-
sidered if the number of analyzed cells was not sufficient. Cell counts at each time-point after
PBSCT were calculated as absolute lymphocyte counts measured in peripheral blood multi-
plied by cell percentages obtained in the lymphoid gate.
T-cell receptor excision circles (sjTRECs) assay. SjTREC quantification was retrospec-
tively performed on cryopreserved PBMCs that were prospectively collected on days 100 and
365 after PBSCT. SjTRECs were quantified by nested real-time PCR, as previously described
(S2 Methods) [29, 30, 32].
Statistical analyses
Clinical outcomes were overall survival (OS), non-relapse mortality (NRM), disease relapse,
clinically significant acute (grade II-IV) and moderate/ severe chronic (NIH 2–3) GVHD, and
infections (bacterial, viral, fungal infections and infection-related mortality). NRM was consid-
ered as time to any death occurring before disease relapse. Clinical outcomes were estimated
using Kaplan-Meier product-limit estimator for overall survival and cumulative incidence
functions were estimated for competing risks analyses. NRM and relapse were considered to be
mutually competing risks. Death was considered as a competing risk for acute and chronic
GVHD. Death and relapse were considered as competing risks for infection. Comparisons of
survival and cumulative incidence functions were performed by log-rank test.
Data concerning immune recovery monitoring were censored at time of relapse/progression
of the underlying disease. The Mann-Whitney rank sum test was used to compare immune
data between ATG-F and control patients, with a p-value<0.05 (2-tailed) considered as signifi-
cant. Stepwise multiple regression analyses were performed to identify potential factors affect-
ing cell subset counts at days 40, 100, 180 and 365. Logarithmic transformation was performed
for cell counts before these analyses, to normalize their distribution. Because of high disequilib-
rium in ATG-F and control patient distribution according to date of transplantation, we could
not enter the period of PBSCT as a covariate in our analysis. To minimize chance of spurious
associations because of multiple comparisons, p<0.01 was considered significant. If
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pretransplant factors were significantly associated with the posttransplant immune cell counts,
we assumed a cause and effect relationship.
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego,
CA) and SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics and clinical outcomes
A total of 65 consecutive patients met inclusion criteria: 37 received pre-transplant ATG-F and
28 did not (control group). Main patient and transplantation characteristics are summarized in
Table 1. ATG-F was administered at a total dose of 45mg/kg in all but 3 ATG-F patients. The
two (control and ATG-F) cohorts were balanced for recipient age, donor age, donor type and
donor/recipient HLA-matching, donor/recipient CMV serostatus, graft composition, condi-
tioning regimen and postgrafting immunosuppression. In accordance with our policy concern-
ing use of ATG-F, there was higher proportions of patients with high or very high risk disease
(as defined by the Disease Risk Index, DRI[33]) in the control group. As also expected, because
of changes in clinical practice concerning use of pre-transplant ATG-F during the study period,
most patients transplanted before 2006 did not receive ATG-F whereas the majority of patients
transplanted in 2006–2012 received ATG-F. This resulted in an unbalanced repartition of
patients between the two cohorts for the period of transplantation. Median follow-up from
PBSCT in surviving patents was 1418 days (range, 843 to 2497) for the global cohort.
No patient experienced primary engraftment failure. Time for neutrophil recovery was
rapid in both groups, although slightly delayed in the ATG-F group. Rapid donor T-cell
engraftment was observed in both groups, with median donor T-cell chimerism levels being
above 95% on day 40 after PBSCT in both groups (S1 Fig). Compared to control patients,
ATG-F patients experienced better overall survival, lower incidence of non-relapse mortality
and similar incidence of relapse at 2 years after PBSCT (Table 1 and S1 Fig). These results
should however be interpreted with caution, given that the choice of giving or not ATG-F was
not random. Confounding factors in our analysis include transplant period and disease risk.
They also had a dramatically lower incidence of acute GVHD at 100 days while the 2-year inci-
dence of chronic GVHD was similar in both groups.
Circulating lymphoid cells–Basic phenotypes (4-color flow cytometry)
Recovery of lymphoid cell subsets in the peripheral blood is shown in Fig 1A–1F. ATG-F and
control patients had similar levels of circulating lymphoid cells during the first year after
PBSCT, except on day 14 when they were lower in ATG-F patients. By assessing lymphoid cell
subsets, we did not observe any difference in levels of NK cells (CD3-CD56+) and CD8+T cells
(CD3+CD8+) between ATG-F and control patients over the first year after PBSCT, with rapid
recovery of these cells in both groups (medians reaching normal values by 40–100 days after
PBSCT). To the contrary, CD4+T cells (CD3+CD4+) recovered more slowly in both groups.
Further, a more profound CD4+T-cell depletion was observed in ATG-F patients the first 6
months after PBSCT, mostly due to slower recovery of naive (CD3+CD4+CD45RA+) cells.
Counts of memory CD4+T cells (CD3+CD4+CD45RO+) were roughly similar in both groups.
Regarding B-cell (CD19+) recovery, median B-cell counts reached normal values 1 year after
PBSCT in both groups. There was a trend for higher B-cell levels in ATG-F patients, although
the difference reached statistical significance only on days 100 and 120 after PBSCT.
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Table 1. Patients characteristics.
Control (N = 28) ATG-F (N = 37) p-value
Patient age, median (range), years 35 (4–55) 40 (4–53) 0.24
Patient gender, male, # of patients (%) 20 (71) 23 (62) 0.43
Disease at transplantation, # of patients *
Acute myeloid leukemia 11 18
Acute lymphoblastic leukemia 7 9
Myeloproliferative disorder 2 1
Myelodysplatic syndrome 2 3
Non-Hodgkin’s lymphoma 4 2
Hodgkin’s lymphoma 1 1
Multiple myeloma 1 1
Aplastic anemia 0 2
Disease risk at transplantationa, # of patients (%) 0.012
Non malignant disease 0 (0) 2 (5)
DRI, low 1 (4) 4 (11)
DRI, intermediate 7 (25) 16 (43)
DRI, high 14 (50) 15 (41)
DRI, very high 6 (21) 0 (0)
Donor age, median (range), years 28 (4–58) 32 (4–54) 0.66
Donor gender, male, # of patients (%) 18 (64) 20 (54) 0.41
Donor type, # of patients (%)
Sibling (HLA-identical) 11 (39) 18 (49) 0.45
Unrelated 17 (61) 19 (51)
Donor-recipient HLA status, # of patients (%)
HLA-matched 21 (75) 29 (78) 0.75
HLA-mismatched 7 (25) 8 (22)
CMV serostatus, donor/patient, # of patients (%)
-/- 11 (39) 13 (35) 0.73
Others 17 (61) 24 (65)
Graft composition, x 106/kg recipient
CD34; median (range) 4.87 (1.32–32.24) 5.25 (0.38–30.74) 0.32
Nucleated cells; median (range) 15.67 (3.35–222.64) 15.88 (4.86–59.12) 0.59
Conditioning regimen, # of patients (%) 0.15
TBI-based (800–1200 cGy) 27 (96) 30 (81)
Busulfan-based (16mg/kg, orally) 1 (4) 4 (11)
Others 0 (0) 3 (8)
Pre-transplant ATG-F, # of patients (%) NA
15mg/kg days -3, -2, -1 NA 34 (92)
20mg/kg day -1 NA 1 (3)
30mg/kg days -5, -4, -3 NA 2 (5)
Postgrafting immunosuppression, # of patients (%)
Cyclosporine + Methotrexate 21 (75) 25 (68) 0.24
Tacrolimus + Methotrexate 2 (7) 8 (22)
Cyclosporine or tacrolimus alone 5 (18) 4 (11)
Year of transplantation, # of patients (%) <0.0001
2000–2005 17 (61) 1 (3)
2006–2012 11 (39) 36 (97)
Neutrophil engraftment b, median (range), days 14.5 (10–19) 17 (11–26) 0.0016
(Continued)
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Circulating lymphoid cells–Detailed phenotypes (8-color flow cytometry)
Naive and memory CD4+ and CD8+ T cells
We further evaluated CD4+ and CD8+T-cell subsets by analyzing CD45RA and CCR7 expression
(Fig 2A–2F). Similar results were observed for absolute counts of naive (CD45RA+CCR7+)
CD4+T cells as those obtained by using 4-color flow cytometry. ATG-F patients also had delayed
recovery of circulating central memory (CD45RA-CCR7+) CD4+T cells up to 1 year after PBSCT.
Moreover, although median levels were within normal values by day 40 in control patients, they
did not reach the normal range in ATG-F patients by 1 year after PBSCT. To the contrary, effec-
tor memory (CD45RA-CCR7-) CD4+T cells reconstituted rapidly in ATG-F and control patients
(medians within normal values on day 40–100 after PBSCT) and no difference was observed
between the two groups.
When looking at the relative proportion of naive and memory subsets among CD4+T cells,
we observed a specific defect of the naive and central memory cell compartments during the
first 6–12 months after PBSCT in ATG-F patients as compared to control patients (p<0.01 on
days 40, 100, 180 and<0.05 on day 365 for the naive subset, and p<0.05 on days 100 and 180
for the central memory subset). This resulted in compensatory higher proportion of effector
memory cells (p<0.01 on days 40, 100, 180 and<0.05 on day 365). A representative diagram
at day 100 is shown in Fig 2G.
Regarding CD8+T cells, median levels of central memory (CD45RA-CCR7+), effector mem-
ory (CD45RA-CCR7-) and CD45RA-re-expressing late effector memory (CD45RA+CCR7-)
CD8+T cells were similar in both groups throughout the study period. Their median counts
reached normal values by day 40–100 after PBSCT. To the contrary, a significant delay in
recovery of naive (CD45RA+CCR7+) CD8+ T cells was observed up to 1 year after PBSCT in
ATG-F patients as compared to control patients. Specifically, while median naive CD8+T-cell
counts were within the normal range by day 40 in control patients, it did not reach the lower
limit of normal range by 1 year after PBSCT in ATG-F patients.
Similarly to what was observed among CD4+T cells, we observed a reduced naive cell com-
partment and larger effector memory cell compartment among CD8+T cells in ATG-F patients
during the first 6 months after PBSCT (p<0.01 on days 40, 100 and 180 for naive subset, and
p<0.01 on day 100 and<0.05 at day 40 and 180 for effector memory subset). No difference
was observed for central memory and CD45RA-re-expressing late effector memory compart-
ments among CD8+T cells. A representative diagram at day 100 is shown in Fig 2H.
Table 1. (Continued)
Control (N = 28) ATG-F (N = 37) p-value
100-day CIfof grade II-IV acute GVHD; % (95% CI) 64.3 (43.0–79.4) 16.2 (6.5–29.9) <0.0001
2-yr CIf of moderate/severe chronic GVHD; % (95% CI) 32.1 (15.4–50.2) 27.3 (14.0–42.5) 0.1265
2-yr CIf of relapse; % (95% CI) 32.1 (15.7–49.9) 21.6 (10.0–36.1) 0.0987
2-yr CIf of non relapse mortality; % (95% CI) 42.9 (24–60.5) 13.5 (4.8–26.6) 0.0023
2-yr overall survival; % (95% CI) 32.1 (16.1–49.3) 72.9 (55.4–84.4) 0.0011
Median follow-up, days, median (range) 1502 (936.5–2497) 1372 (843–2098) 0.58
CIf indicates cumulative incidence function; NA, not applicable.
* No statistical test is provided due to small sample size.
a classiﬁed according to Armand et al. [33].
b Absolute neutrophil counts >0.5 x109/L for at least consecutive 3 days.
doi:10.1371/journal.pone.0130026.t001
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Fig 1. Lymphoid cell recovery after PBSCTwith or without pre-transplant ATG-F. Levels of circulating
lymphoid cells in the peripheral blood of ATG-F (blue box) and control (white box) patients are shown. Cell
phenotypes were assessed for 27/34, 27/33, 27/31, 26/30, 24/30, 26/29 and 19/25 disease-free survivors in
the ATG-F cohort on days 40, 60, 80, 100, 120, 180 and 365 after PBSCT, respectively; and for 17/23, 11/19,
10/17, 12/17, 11/17, 8/15 and 5/9 disease-free survivors in the control cohort on days 40, 60, 80, 100, 120,
Immune Recovery after PBSCT with ATG-F
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Regulatory T cells (Treg). Treg (CD4+CD127neg/lowFoxP3+) were also analyzed. No dif-
ference was observed in either their absolute number or their relative proportion among
CD4+T cells between ATG-F and control patients (S2A and S2B Fig). Their recovery after
PBSCT was slow in both groups, with the median of their absolute levels reaching normal val-
ues only by day 365 in control patients and lagging below the lower limit of normal range for at
least 1 year in ATG-F patients (p = NS).
B cells, NK cells and invariant NKT cells (iNKT). Recovery of total B cells (CD19+) and
their naive (CD27-IgD+), unswitched memory [CD27+IgD+] and switched memory [CD27+-
IgD-] subsets was mainly superimposable in ATG-F and control patients (S2C–S2E Fig). Con-
trary to what was observed for T-cell subsets, most of circulating B cells were of naive
phenotype during the first year after PBSCT. Naive B-cell counts recovered at day 365 whereas
switched memory B-cell recovery was not achieved by 1 year after PBSCT.
NK-cell recovery was similar in both groups, with faster recovery of CD56brightNK cells
(CD3-CD56brightCD16-) in comparison with CD56dimNK cells (CD3-CD56dim CD16+) (S2F
and S2G Fig).
Finally, as observed in healthy donors, levels of iNKT cells (CD3+CD56+TCR-Vα24Jα18+-
TCR-Vβ11+) were very low in the peripheral blood of transplanted patients. Medians were
within normal values throughout the study period, except at day 40 for ATG-F patients when it
lagged below the lower limit of normal range (p<0.05 compared to control patients) (S2H
Fig).
Circulating recent thymic emigrants (RTE) (sjTREC level quantification
and flow cytometry)
Since naive T-cell subset recovery appeared to be severely affected in ATG-F patients, we fur-
ther delineated the presence of circulating RTE, in order to determine the thymic output of
naive T cells. Levels of RTE were analyzed both by sjTREC quantification for total T cells and
by flow cytometry for CD4+RTE (CD4+CD45RA+CCR7+CD31+), with a significant correlation
between the two techniques (p = 0.005) (Fig 3). There was a trend for lower sjTREC counts on
day 100 in ATG-F compared to control patients (p = 0.09), but the difference receded on day
365 and sjTRECs levels significantly increased from day 100 to day 365 in ATG-F patients.
Similar results were observed for CD4+RTE by flow cytometry, but the difference was signifi-
cant on day 100 between ATG-F and control patients using this method assessing only the
CD4+T-cell compartment. Overall, these results suggest that ATG-F unlikely impaired thymo-
poiesis from day 100 to 1 year after PBSCT.
Multiple regression analysis of factors affecting CD4+ and CD8+ T-cell
subset recovery
In order to evaluate whether pre-transplant ATG-F indeed independently impacted levels of
CD4+T cells (total, naive and central memory cells) and naive CD8+T cells over the first year
after PBSCT, we performed multiple regression analyses. Tested co-variables included pre-
transplant parameters and occurrence of grade II-IV acute GVHD (before the day of immune
cell assessment) because of the significant difference we observed in its cumulative incidence
between ATG-F and control patients (see above). Results are presented in Table 2.
180 and 365 after PBSCT, respectively. Box and whisker plots display the median, 25th and 75thpercentiles of
the distribution (box) and whiskers extend to 5th and 95th percentiles. The grey horizontal line and shaded
grey area show the median and normal range (from 5th to 95th percentile) in 22 age-matched healthy controls.
*p <0.05; ** p<0.01.
doi:10.1371/journal.pone.0130026.g001
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Interestingly, ATG-F was the sole factor significantly impacting both short- and long-term
(from day 40–100 to day 365) recovery of naive CD4+ and CD8+T cells and of central memory
Fig 2. Recovery of CD4+ and CD8+ T-cell subsets after PBSCT with or without pre-transplant ATG-F.
Circulating immune cells phenotypes were assessed for 31/34, 26/30, 28/29 and 20/25 disease-free
survivors in the ATG-F cohort on days 40, 100, 180 and 365 after PBSCT, respectively; and for 6/23, 15/17,
9/15 and 7/9 disease-free survivors in the control cohort on days 40, 100, 180 and 365 after PBSCT,
respectively. A-F) Absolute cell counts in the peripheral blood of ATG-F (blue box) and control (white box)
patients are shown. Box and whisker plots display the median, 25th and 75th percentiles of the distribution
(box) and whiskers extend to 5th and 95th percentiles. The grey horizontal line and shaded grey area show the
median and normal range (from 5th to 95th percentile) in 22 age-matched healthy controls. G-H) Relative
proportions of naïve and memory subsets among CD4+ (G) and CD8+ (H) T compartments were assessed,
according to pre-transplant ATG-F or not. Mean and standard deviation are shown. *p <0.05; ** p<0.01.
doi:10.1371/journal.pone.0130026.g002
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Fig 3. Circulating recent thymic emigrants after PBSCTwith or without pre-transplant ATG-F. Levels of
circulating RTE in the peripheral blood of ATG-F (blue box) and control (white box) patients are shown. A)
RTE were assessed by sjTRECs quantification assay for 30/30 and 23/25 disease-free survivors in the
ATG-F cohort on days 100 and 365 after PBSCT, respectively; and for 11/17 and 7/9 disease-free survivors
in the control cohort on days 100 and 365 after PBSCT, respectively. B) RTE were assessed by flow
cytometry for 26/30 and 20/25 disease-free survivors in the ATG-F cohort on days 100 and 365 after PBSCT,
respectively; and for 15/17 and 7/9 disease-free survivors in the control cohort on days 100 and 365 after
PBSCT, respectively. Box and whisker plots display the median, 25th and 75th percentiles of the distribution
(box) and whiskers extend to 5th and 95th percentiles. The grey horizontal line and shaded grey area show the
median and normal range (from 5th to 95th percentile) in 22 age-matched healthy controls.
doi:10.1371/journal.pone.0130026.g003
Table 2. Multivariate analysis of factors impacting immune cell levels after myeloablative PBSCT.
Immune cell subsets Signiﬁcant factors Coefﬁcient (SE) p
Total CD4+ T cells day 40 ATG-F -1.55 (0.36) <0.0001
Acute GVHD -1.22 (0.37) 0.0024
day 100 ATG-F -1.22 (0.24) <0.0001
day 180 -
day 365 -
Naive CD4+ T cells day 40 ATG-F -3.42 (0.40) <0.0001
Recipient’s age -0.036 (0.012) 0.0070
day 100 ATG-F -3.42 (0.47) <0.0001
day 180 ATG-F -2.52 (0.73) 0.0020
day 365 ATG-F -1.74 (0.60) 0.0089
Central memory CD4+ T cells day 40 -
day 100 ATG-F -1.44 (0.35) 0.0003
day 180 -
day 365 ATG-F -1.81 (0.60) 0.006
Naive CD8+ T cells day 40 ATG-F -2.47 (0.82) 0.0048
day 100 ATG-F -1.18 (0.35) 0.0017
day 180 ATG-F -1.77 (0.58) 0.0045
day 365 ATG-F -1.71 (0.48) 0.0016
Tested variables included: use of pre-transplant ATG-F, patient’s age, donor’s age, type of donor (related or unrelated), donor/patient HLA-match (HLA-
matched or HLA-mismatched), donor/patient CMV serostatus (-/-or all other combinations), CD34+ cell dose (log-transformed), postgrafting
immunosuppression (cyclosporine+methotrexate, tacrolimus+methotrexate or cyclosporine/tacrolimus alone) and acute GVHD (if it occurred before the
day of immune cell assessment). To minimize chance of spurious associations because of multiple comparisons, p <0.01 was considered signiﬁcant. Only
signiﬁcant variables are shown.
doi:10.1371/journal.pone.0130026.t002
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CD4+T cells. It also significantly impacted short-term (days 40 and 100) total CD4+T-cell lev-
els. Similarly, acute GVHD had a negative impact on total CD4+ T-cell counts.
Infections
The 2-year cumulative incidence of infection-related death was 8.1% (95% CI, 2.0–19.8%) and
10.9% (95% CI, 2.7–25.7%) in ATG-F and control patients, respectively (p = 0.64). No signifi-
cant difference was observed in the 2-year cumulative incidences of serious bacterial, viral and
fungal infections, between ATG-F and control patients (Fig 4). Numbers of serious infections
by post-transplant time period (days 0–40, 41–180, 181–365 and 366–730) are shown in S1
Table. There was no difference in numbers of bacterial, viral or fungal infections between
ATG-F and control patients, with the exception of the 181–365 day-period when higher num-
bers of bacterial infections were observed in control patients. No case of PTLD was diagnosed
during the study period. Two EBV-viremia were observed after 2006. Both of them occurred in
patients who received pre-transplant ATG-F, during the early post-transplant period (0–40
days after PBSCT). None of them resulted in PTLD. Three parasitic infections were observed
during the study follow-up, each of them in the ATG-F group. However, because of their rarity,
no conclusion might be driven for comparison between ATG-F and control patients. Overall,
we did not observe higher rate of total serious infections in ATG-F in comparison with control
patients. However, a confounding factor in our analysis might have been the higher incidence
of acute GVHD in control patients since GVHD (and its treatment) is a known risk factor for
infections.
Discussion
Although pre-transplant infusion of ATG-F is broadly used for GVHD prevention after alloge-
neic PBSCT, its impact on immune reconstitution is still poorly documented. Here, we
reported longitudinal monitoring of immune recovery after myeloablative PBSCT and assessed
the impact of pre-transplant ATG-F. We observed that pre-transplant infusion of ATG-F had
a long-lasting impact on reconstitution of the T-cell pool in the peripheral blood. However,
ATG-F patients did not experience higher incidence or higher rate of serious infections after
PBSCT.
In comparison with previous reports having focused on ATG-T [16, 17], we observed that
pre-transplant infusion of ATG-F similarly impaired recovery of naive CD4+ and naive CD8+T
cells up to at least 1 year after PBSCT. Looking precisely at memory T cells, we observed that
ATG-F also selectively depleted central memory CD4+T cells but did not compromise effector
Fig 4. Cumulative incidence of infections after PBSCT with or without ATG-F.Cumulative incidences of bacterial (A), viral (B) and fungal (C) infections
in ATG-F (solid line) and control (broken line) patients are shown.
doi:10.1371/journal.pone.0130026.g004
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memory CD4+ and CD8+T-cell recovery. ATG-F was even associated with compensatory
higher proportion of effector memory CD8+ T cells, mainly because of naive cell depletion.
ATG-F did neither decrease levels of Treg, B, iNKT nor NK cells. Mechanisms by which pre-
transplant ATG-F selectively impairs naïve T-cell and central memory CD4+T-cell recovery
are not well documented. It is now widely accepted that reconstitution of the T-cell pool after
transplantation arises from both homeostatic peripheral expansion (HPE) of donor T cells pas-
sively transferred with the graft, and naive T-cell neo-production by the thymus (reviewed in
[34, 35]). In patients given high-intensity conditioning, most circulating T cells during the first
months post-transplantation are the progeny of HPE. Based on previous pharmacokinetic
analyses having shown that ATG preparations persist for several weeks after administration[8,
9], it can be postulated that pre-transplant ATG-F in vivo modulates the composition of the
graft by depleting subsets of donor immune cells early after graft infusion. Our results suggest
that ATG-F selectively depletes donor naive T cells and central memory CD4+T cells, while it
relatively spares other T cells. Consistently, differential cytotoxic effects of ATG have been
reported in the setting of solid organ transplantation and demonstrated in vitro[36]. Whether
this is due to selective effects of ATG or to cell-specific intrinsic resistance to ATG-mediated
depletion is unknown. Moreover, it is also known that HPE occurs asymmetrically among T
cells, with CD8+T cells (especially memory cells) being more prone to undergo HPE than
CD4+T cells and naive T cells[37]. Hence, such differences in HPE propensity among T-cell
subsets may have subsequently maintained, or even amplified, long-term differences in T-cell
subset recovery. In addition, a third hypothesis for the relative depletion of naive T-cell com-
partment and compensatory expansion of effector memory T-cell compartment in ATG-F
patients may be that ATG-F induces switch in cell phenotype, given that ATG-F also contains
activating T-cell antibodies (i.e. anti-CD3 antibodies) that could promote a memory
phenotype.
Levels of naive CD4+T cells in ATG-F patients were low up to day 120 after PBSCT and
began to increase from day 180–365 after PBSCT. This tempo likely corresponds to new waves
of naive cells originating from the thymus. Hence, we evaluated ATG-F effects on thymic-
dependent T-cell neo-generation by both sjTRECs quantification and flow cytometry assays.
By comparison with control patients, patients who received pre-transplant ATG-F had lower
levels of circulating RTE on day 100. Similar results were reported after ATG-T-conditioned
transplantation [17, 19]. It is not excluded that ATG-F might have impaired early thymopoiei-
sis (prior to day 100). However, because thymic-dependent T-cell neo-generation after myeloa-
blative transplantation almost takes place beyond day 100[35, 38], another plausible hypothesis
is that the low levels of RTE in ATG-F patients on day 100 might have also resulted from
peripheral destruction of donor RTE that had been passively transferred with the graft. There-
after, no more difference was observed in RTE levels on day 365 and their counts significantly
increased from day 100 to day 365 in ATG-F patients, suggesting that ATG-F unlikely impairs
thymopoiesis at 1-year after PBSCT. To the contrary, such significant increase in RTE levels
from day 100 to day 365 was not observed in control patients. Hypothesis might be lower thy-
mic output in these patients because of higher rate of acute GVHD [39]. Therefore, ATG-F
might have helped to maintain thymic functions after PBSCT by preventing GVHD-induced
thymic damages.
As discussed above, we observed that use of pre-transplant ATG-F significantly modified
the composition of circulating T cells up to at least 6–12 months after PBSCT, with most CD4+
and CD8+T cells in the peripheral blood of ATG-F patients being of effector memory pheno-
type while naive cells being almost absent. It is known that effector memory cells play major
role in transfer of anti-pathogen T-cell memory from the donor to the recipient after transplan-
tation [40]. There is also accumulating evidence that effector memory T cells poorly mediate
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GVHD reactions [40–42] and that donor T cells that promote GVHDmainly reside within the
naive T cell compartment [43, 44]. Hence, the early shift in T-cell phenotype in favor of effector
memory and disfavor of naive subsets after ATG-F might be one of the mechanisms by which
use of pre-transplant ATG-F did not result in higher incidence/rate of serious infectious com-
plications but contributed to lower incidence of acute GVHD in our cohort. In addition, it
appeared in our study that ATG-F spared B and NK cells, which might also have contributed
to anti-pathogen defenses. On the other hand, Treg were similarly not affected by pre-trans-
plant ATG-F. Since these cells can mediate immune tolerance [45, 46], their persistence might
have also prevented GVHD. Eventually, as discussed above, naive T cells that emerged only tar-
dily (6–12 months) after ATG-F PBSCT were likely RTE that have been educated in the recipi-
ent’s thymus. Hence, these cells were likely tolerant to recipient’s tissues antigens and less
prone to promote GVHD.
Clinical outcomes of our cohorts have obviously been influenced by improvements in clini-
cal practice and supportive care that occurred over the study period (from 2000 to 2012). Since
distribution of ATG-F and control patients was not symmetrical according to date of PBSCT, it
is plausible that the period of PBSCT also contributed to lower incidences of non-relapse mor-
tality and infection among ATG-F patients. To the contrary, it is unlikely that the period of
PBSCT impacted GVHD incidence and immune recovery. Because of the retrospective nature
of our study and the heterogeneity of our cohorts, no firm recommendation can be driven
from this study concerning the use of ATG-F before PBSCT in the clinic. The aim of this study
was to assess the imprint of pre-transplant ATG-F on the circulating immune cell pool after
myeloablative PBSCT and to raise some hypotheses about the mechanistic pathways by which
pre-transplant ATG-F may influence post-transplant outcomes.
In conclusion, our study suggests that pre-transplant ATG-F induces long-lasting modula-
tion of the circulating immune cell pool after myeloablative PBSCT. Whether this may consti-
tute one mechanism by which ATG-F prevents GVHD reactions without deeply
compromising anti-pathogen defenses has to be confirmed in further studies.
Supporting Information
S1 Fig. Outcomes after PBSCT with or without ATG-F. A) Kinetics of donor T-cell chime-
rism in patients who received (blue box) or not (white box) pre-transplant ATG-F. Box and
whisker plots display the median, 25th and 75th percentiles of the distribution (box) and whis-
kers extend to 5th and 95th percentiles.; B-F) Post-transplant outcomes of patients who
received (solid line) or not (broken line) pre-transplant ATG-. Overall survival (B) and cumu-
lative incidences of non-relapse mortality (NRM) (C); relapse (D); grade II-IV acute GVHD
(E) and moderate/severe chronic GVHD (F).
(TIF)
S2 Fig. Treg, B, NK and iNKT cell recovery after PBSCT with or without pre-transplant
ATG-F. Levels of circulating Treg (A, B), B cells (C-E), NK cells (F, G) and iNKT cells (I) in
the peripheral blood of ATG-F (blue box) and control (white box) patients. Circulating
immune cells phenotypes were assessed for 31/34, 26/30, 28/29 and 20/25 disease-free survi-
vors in the ATG-F cohort on days 40, 100, 180 and 365 after PBSCT, respectively; and for 6/23,
15/17, 9/15 and 7/9 disease-free survivors in the control cohort on days 40, 100, 180 and 365
after PBSCT, respectively. Box and whisker plots display the median, 25th and 75th percentiles
of the distribution (box) and whiskers extend to 5th and 95th percentiles. The grey horizontal
line and shaded grey area show the median and normal range (from 5th to 95th percentile) in
22 age-matched healthy controls.
(TIF)
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